Pub Date : 2025-01-07DOI: 10.1016/s1473-3099(25)00002-7
Garcia Quesada M, Peterson ME, Bennett JC, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7—In this Article, Tine Dalby should have had the additional affiliation “Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark”. This correction has been made to the online version as of Jan 7, 2025, and will be made to the printed version.
{"title":"Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7","authors":"","doi":"10.1016/s1473-3099(25)00002-7","DOIUrl":"https://doi.org/10.1016/s1473-3099(25)00002-7","url":null,"abstract":"<em>Garcia Quesada M, Peterson ME, Bennett JC, et al. Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.</em> Lancet Infect Dis <em>2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7</em>—In this Article, Tine Dalby should have had the additional affiliation “Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark”. This correction has been made to the online version as of Jan 7, 2025, and will be made to the printed version.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"84 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-07DOI: 10.1016/s1473-3099(24)00675-3
Nicola Jungbäck, Yannik Vollmuth, Tatiana Mögele, Przemyslaw Grochowski, Jürgen Schlegel, Tina Schaller, Bruno Märkl, Christiane Herden, Kaspar Matiasek, Dennis Tappe, Friederike Liesche-Starnecker
Borna disease, which is a severe encephalitis that primarily affects horses and sheep, has been recognised for over two centuries. Borna disease virus 1 (BoDV-1) has been identified as a cause of a predominantly fatal encephalitis in humans. Little scientific data exist regarding the virus' transmission, entry portal, and excretion routes. Lesional patterns, immunological responses, and pathogenetic mechanisms remain largely unexplored in both reservoir and dead-end hosts. This systematic review compiles current knowledge on these aspects and provides guidance for future research. PubMed, ScienceDirect, and EBSCO were searched for publications from Jan 1, 2000, to April 30, 2024. 823 records were found, of which 41 studies were included. This systematic review discusses BoDV-1 transmission, pathogenesis, histopathological changes, and immunology in both reservoir and dead-end hosts, with special regard for humans. The exact propagation mechanisms, entry portal, and viral spread within the CNS are not entirely clear in humans. Although more data exist in animals, much remains hypothetical. Future research should focus on identifying potential entry sites and viral spread in dead-end hosts, which could help to clarify the pathogenesis and lesion distribution in the CNS, thereby contributing to a better understanding of BoDV-1 infection in humans and parallels with animal infections.
{"title":"Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review","authors":"Nicola Jungbäck, Yannik Vollmuth, Tatiana Mögele, Przemyslaw Grochowski, Jürgen Schlegel, Tina Schaller, Bruno Märkl, Christiane Herden, Kaspar Matiasek, Dennis Tappe, Friederike Liesche-Starnecker","doi":"10.1016/s1473-3099(24)00675-3","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00675-3","url":null,"abstract":"Borna disease, which is a severe encephalitis that primarily affects horses and sheep, has been recognised for over two centuries. Borna disease virus 1 (BoDV-1) has been identified as a cause of a predominantly fatal encephalitis in humans. Little scientific data exist regarding the virus' transmission, entry portal, and excretion routes. Lesional patterns, immunological responses, and pathogenetic mechanisms remain largely unexplored in both reservoir and dead-end hosts. This systematic review compiles current knowledge on these aspects and provides guidance for future research. PubMed, ScienceDirect, and EBSCO were searched for publications from Jan 1, 2000, to April 30, 2024. 823 records were found, of which 41 studies were included. This systematic review discusses BoDV-1 transmission, pathogenesis, histopathological changes, and immunology in both reservoir and dead-end hosts, with special regard for humans. The exact propagation mechanisms, entry portal, and viral spread within the CNS are not entirely clear in humans. Although more data exist in animals, much remains hypothetical. Future research should focus on identifying potential entry sites and viral spread in dead-end hosts, which could help to clarify the pathogenesis and lesion distribution in the CNS, thereby contributing to a better understanding of BoDV-1 infection in humans and parallels with animal infections.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"15 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-07DOI: 10.1016/s1473-3099(24)00860-0
Nebiyu Dereje, Mosoka Papa Fallah, Raji Tajudeen, Jean Kaseya
No Abstract
{"title":"A new RH5.1/Matrix-M candidate malaria vaccine: a promising finding to boost malaria elimination in Africa","authors":"Nebiyu Dereje, Mosoka Papa Fallah, Raji Tajudeen, Jean Kaseya","doi":"10.1016/s1473-3099(24)00860-0","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00860-0","url":null,"abstract":"No Abstract","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"133 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-06DOI: 10.1016/s1473-3099(24)00834-x
Silvano Wendel, Roberta Fachini, Ruth Achkar, Patrícia Scuracchio, Lara Faria Dias
We read the Correspondence by Flávia Jacqueline Almeida and colleagues1 with interest. Dengue has affected millions of people annually, with many asymptomatic cases, where the likelihood of viraemic (RNAaemic) blood donors cannot be disregarded.
{"title":"Additional questions regarding transfusion-transmitted dengue virus in Brazil","authors":"Silvano Wendel, Roberta Fachini, Ruth Achkar, Patrícia Scuracchio, Lara Faria Dias","doi":"10.1016/s1473-3099(24)00834-x","DOIUrl":"https://doi.org/10.1016/s1473-3099(24)00834-x","url":null,"abstract":"We read the Correspondence by Flávia Jacqueline Almeida and colleagues<span><span><sup>1</sup></span></span> with interest. Dengue has affected millions of people annually, with many asymptomatic cases, where the likelihood of viraemic (RNAaemic) blood donors cannot be disregarded.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":"138 1","pages":""},"PeriodicalIF":56.3,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-09-02DOI: 10.1016/S1473-3099(24)00421-3
Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, Andrea T Hooper, Alina Baum, Christopher D Petro, Faisal A Fakih, M Juliana McElrath, Stephen C De Rosa, Kristen W Cohen, LaTonya D Williams, Caleb A Hellman, Ahmad J Odeh, Aloki H Patel, Georgia D Tomaras, Gregory P Geba, Christos A Kyratsous, Bret Musser, George D Yancopoulos, Gary A Herman
<p><strong>Background: </strong>Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.</p><p><strong>Methods: </strong>This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.</p><p><strong>Findings: </strong>Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280-450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (
背景：我们需要更深入地了解单克隆抗体（mAb）在针对相同蛋白时如何影响疫苗介导的免疫反应。我们描述了首个前瞻性随机试验，旨在了解由 mAb 介导的疫苗诱导的对 SARS-CoV-2 尖峰蛋白表位的免疫反应的改变：这项随机、开放标签、平行分组的研究评估了一种 mAb 复方制剂（卡西利单抗和伊马单抗）与一种疫苗（Moderna 的 mRNA-1273 疫苗）之间的潜在相互作用。参与者根据计算机生成的随机方案按年龄分层随机分配（根据预先指定的报名波次内的随机分配比例）（研究结果：2021年4月29日至2021年6月30日）：2021年4月29日至2022年11月21日期间，807名参与者接受了资格评估，295名参与者被随机分配。293名参与者被纳入安全性分析集，260名参与者被纳入按方案分析集。所有接种者都产生了SARS-CoV-2中和抗体，针对SARS-CoV-2 D614G变异株（最初开发COVID-19疫苗时被认为是参考株）的抗体滴度中位数高于已公布的保护性阈值（100 IU/mL）。如果在接种疫苗前 85 天或更短时间内接种卡西利韦单抗和依维莫司（静脉注射 150-1200 毫克），或在接种疫苗时同时皮下注射（600 毫克或 1200 毫克），滴度下降达 4 倍（卡西利韦单抗和依维莫司的中位滴度为 280-450 IU/毫升，而仅接种疫苗的中位滴度为第 56 天 1160 IU/毫升）。48毫克和12毫克静脉注射组的中和滴度降低幅度最小，分别相当于在接种疫苗前113天和169天接种卡西利韦单抗和伊马单抗，以及在注射mAb前6天接种疫苗。在所有组别中，mAb对疫苗诱导的总抗体和T细胞对尖峰蛋白的反应影响极小。卡西利单抗和伊马单抗加mRNA-1273的耐受性总体良好；与仅接种疫苗组相比，卡西利单抗和伊马单抗加疫苗组的治疗引起的不良事件略有增加：解读：在接种COVID-19疫苗之前或同时接种卡西利单抗和伊马单抗可减少SARS-CoV-2中和抗体的激发，但如果在接种前接种mAb，则效果甚微。虽然这种中和作用下降的临床意义尚不清楚，但这一证据表明，在临床上同时使用以相同病毒蛋白为主要作用方式的 mAb 和疫苗来预防或治疗传染病之前，有必要对潜在的相互作用进行进一步调查：资金来源：Regeneron Pharmaceuticals 和 F Hoffmann-La Roche。
{"title":"Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.","authors":"Flonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, Jennifer D Hamilton, Benjamin A Olenchock, Taylor Brackin, Samit Ganguly, Eduardo Forleo-Neto, Lori Faria, Ingeborg Heirman, Mary Marovich, Julia Hutter, Laura Polakowski, Susan C Irvin, Mazhar Thakur, Andrea T Hooper, Alina Baum, Christopher D Petro, Faisal A Fakih, M Juliana McElrath, Stephen C De Rosa, Kristen W Cohen, LaTonya D Williams, Caleb A Hellman, Ahmad J Odeh, Aloki H Patel, Georgia D Tomaras, Gregory P Geba, Christos A Kyratsous, Bret Musser, George D Yancopoulos, Gary A Herman","doi":"10.1016/S1473-3099(24)00421-3","DOIUrl":"10.1016/S1473-3099(24)00421-3","url":null,"abstract":"<p><strong>Background: </strong>Deeper insight is needed on how monoclonal antibodies (mAbs) affect vaccine-mediated immune responses when targeting the same protein. We describe the first prospective randomised trial designed to understand mAb-mediated alterations in vaccine-induced immune responses to SARS-CoV-2 spike protein epitopes.</p><p><strong>Methods: </strong>This randomised, open-label, parallel-group study assessed the potential interaction of a mAb combination, casirivimab and imdevimab, with a vaccine, Moderna's mRNA-1273, in healthy SARS-CoV-2 immunologically naive, seronegative adults at six centres in the USA. Participants were randomly assigned (per prespecified randomisation ratios within enrolment waves) according to a computer-generated randomisation scheme, stratified by age (<65 years and ≥65 years), to various intravenous or subcutaneous doses of casirivimab and imdevimab before, after, or at the same time as mRNA-1273 or to mRNA-1273 only. The doses of casirivimab and imdevimab were chosen to mimic various time intervals between receipt of 1200 mg of the mAb and the first dose of a primary series with mRNA-1273. The primary endpoint was vaccine-induced 50% inhibitory dilution neutralising antibody titres to SARS-CoV-2 spike protein, 56 days after the first vaccination. Secondary endpoints included vaccine-induced total antibodies to SARS-CoV-2 antigens and incidence of treatment-emergent adverse events. Exploratory endpoints included blood-derived T-cell and B-cell responses. The per-protocol set was used for the analysis of the primary endpoint and included all randomly assigned participants who received both doses of the vaccine and completed the injection or infusion of casirivimab and imdevimab per protocol, had no evidence of SARS-CoV-2 infection in the past or in the 56 days after the first dose of vaccine, and did not receive any intervention outside of the study that could alter the immune response. Safety was assessed in the safety analysis set, which included all randomly assigned participants who had received one or more doses of mRNA-1273 or any study drug, and analysed based on treatment received. The study is registered with ClinicalTrials.gov, NCT04852978, and is complete.</p><p><strong>Findings: </strong>Between April 29, 2021, and Nov 21, 2022, 807 participants were assessed for eligibility and 295 were randomly assigned. 293 participants were included in the safety analysis set and 260 were included in the per-protocol set. All vaccinated participants developed neutralising antibodies to SARS-CoV-2, with median titres above the published protective threshold (100 IU/mL) against the SARS-CoV-2 D614G variant (considered a reference strain at the time the initial COVID-19 vaccines were developed). Titres were decreased up to 4-fold (median titres 280-450 IU/mL for casirivimab and imdevimab vs 1160 IU/mL for vaccine only on day 56) when casirivimab and imdevimab was given 85 days or less before vaccination (","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"52-67"},"PeriodicalIF":36.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-09-23DOI: 10.1016/S1473-3099(24)00594-2
Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur
The global health community has had more than a decade to develop pandemic preparedness programmes and apply lessons learnt to new disease outbreaks. Mpox has now been declared a global public health emergency, but the response appears to be missing important elements of equity, focusing instead on diagnosis and surveillance. This approach leaves vulnerable populations in countries grappling with the outbreak without the preventive and treatment services they need. Based on our experiences managing the current mpox outbreak in Burundi, we outline some limitations of ongoing response strategies and advocate for the adoption of core principles that emphasise an equitable approach. These strategies include: community partnerships; care provided across the spectrum of disease; gender-informed services; sensitive community education; and promotion of community cohesion. Although funding and implementing these activities is ultimately the responsibility of governments, additional support might be needed also from non-governmental organisations, especially in settings characterised by conflict and fledgling health systems where the current mpox outbreak is centred.
{"title":"A pox on all our houses: a missing component in the global mpox response is equity.","authors":"Eddy Jonas, Nesar Hamraz, Nathalie Marcadieu, Daphnee Salomon, Deogratias Niyizonkiza, Jennifer Furin, Jacklin Saint Fleur","doi":"10.1016/S1473-3099(24)00594-2","DOIUrl":"10.1016/S1473-3099(24)00594-2","url":null,"abstract":"<p><p>The global health community has had more than a decade to develop pandemic preparedness programmes and apply lessons learnt to new disease outbreaks. Mpox has now been declared a global public health emergency, but the response appears to be missing important elements of equity, focusing instead on diagnosis and surveillance. This approach leaves vulnerable populations in countries grappling with the outbreak without the preventive and treatment services they need. Based on our experiences managing the current mpox outbreak in Burundi, we outline some limitations of ongoing response strategies and advocate for the adoption of core principles that emphasise an equitable approach. These strategies include: community partnerships; care provided across the spectrum of disease; gender-informed services; sensitive community education; and promotion of community cohesion. Although funding and implementing these activities is ultimately the responsibility of governments, additional support might be needed also from non-governmental organisations, especially in settings characterised by conflict and fledgling health systems where the current mpox outbreak is centred.</p>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"e44-e46"},"PeriodicalIF":36.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vaccination has been shown to be the most effective means of preventing infectious diseases, although older people commonly have a suboptimal immune response to vaccines and thus impaired protection against subsequent adverse outcomes. This Review provides an overview of the existing mechanistic insights into compromised vaccine response for respiratory infectious diseases in older people, defined as aged 65 years and older, including immunosenescence, epigenetic regulation, trained immunity, and gut microbiota. We further summarise the latest proven or potential strategies to strengthen weakened immunogenicity. Insights from these analyses will be conducive to the development of the next generation of vaccines.
{"title":"Optimising vaccine immunogenicity in ageing populations: key strategies.","authors":"Guangzhen Jiang, Yushu Zou, Dongyu Zhao, Jingyou Yu","doi":"10.1016/S1473-3099(24)00497-3","DOIUrl":"10.1016/S1473-3099(24)00497-3","url":null,"abstract":"<p><p>Vaccination has been shown to be the most effective means of preventing infectious diseases, although older people commonly have a suboptimal immune response to vaccines and thus impaired protection against subsequent adverse outcomes. This Review provides an overview of the existing mechanistic insights into compromised vaccine response for respiratory infectious diseases in older people, defined as aged 65 years and older, including immunosenescence, epigenetic regulation, trained immunity, and gut microbiota. We further summarise the latest proven or potential strategies to strengthen weakened immunogenicity. Insights from these analyses will be conducive to the development of the next generation of vaccines.</p>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"e23-e33"},"PeriodicalIF":36.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：